US6054561A
(en)
*
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5032521A
(en)
*
|
1984-12-05 |
1991-07-16 |
The Salk Institute For Biological Studies |
Monoclonal antibody specific for a mammary tumor cell surface antigen
|
AU601379B2
(en)
*
|
1985-11-07 |
1990-09-13 |
Trustees Of Columbia University In The City Of New York, The |
Antigen indicative of human breast cancer and assays based thereon
|
US6861511B1
(en)
|
1986-06-04 |
2005-03-01 |
Bayer Corporation |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US5401638A
(en)
*
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US4894227A
(en)
*
|
1986-08-01 |
1990-01-16 |
Cetus Corporation |
Composition of immunotoxins with interleukin-2
|
US6004761A
(en)
*
|
1986-11-19 |
1999-12-21 |
Sanofi |
Method for detecting cancer using monoclonal antibodies to new mucin epitopes
|
AU613590B2
(en)
*
|
1986-11-19 |
1991-08-08 |
Bristol-Myers Squibb Company |
Hybridomas producing monoclonal antibodies to new mucin epitopes
|
US4863726A
(en)
*
|
1987-05-29 |
1989-09-05 |
Cetus Corporation |
Combination therapy using immunotoxins with interleukin-2
|
US5084266A
(en)
*
|
1988-02-03 |
1992-01-28 |
The University Of Melbourne |
Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
|
US5681543A
(en)
*
|
1988-02-29 |
1997-10-28 |
Shering Aktiengesellschaft |
Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
|
US5948647A
(en)
*
|
1990-10-29 |
1999-09-07 |
Chiron Corporation |
Nucleic acids encoding antigen-binding sites specific for cancer antigens
|
US5849877A
(en)
*
|
1990-10-29 |
1998-12-15 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5811267A
(en)
*
|
1990-10-29 |
1998-09-22 |
Chiron Corporation |
Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
|
US5292524A
(en)
*
|
1991-09-06 |
1994-03-08 |
California Institute Of Technology |
Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
|
DE69334255D1
(de)
*
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US7255851B2
(en)
*
|
1994-07-01 |
2007-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
DE10141937A1
(de)
*
|
2001-08-28 |
2003-03-27 |
Alfred Schmidt |
Markierung der Aromatase
|
DE60233744D1
(de)
|
2001-09-20 |
2009-10-29 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
AU2003218350A1
(en)
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US6916474B2
(en)
|
2002-07-15 |
2005-07-12 |
Board Of Regents, The University Of Texas System |
Antibodies with increased affinities for anthrax antigens
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20040170982A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
AU2004213452A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
EP1708752B1
(de)
*
|
2004-01-27 |
2012-02-22 |
University Of Southern California |
Therapeutisches krebsmittel mit polymergebundenem antikörper
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
JP5085326B2
(ja)
|
2004-09-18 |
2012-11-28 |
ユニバーシティ オブ メリーランド,ボルチモア |
NCCa−ATPチャネルを標的とする処置剤およびその使用方法
|
US10583094B2
(en)
|
2004-09-18 |
2020-03-10 |
University Of Maryland |
Therapeutic methods that target the NCCA-ATP channel
|
LT3264094T
(lt)
|
2005-04-04 |
2021-04-12 |
Biogen Ma Inc. |
Imuninio atsako į terapijos agentą įvertinimo būdai
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
CA2604885A1
(en)
|
2005-04-07 |
2006-10-19 |
Guoying Yu |
Cacna1e in cancer diagnosis, detection and treatment
|
WO2007061684A1
(en)
|
2005-11-18 |
2007-05-31 |
Board Of Regents, The University Of Texas System |
Quantification of fusion proteins and their activity from chromosomal translocation
|
RU2503463C2
(ru)
|
2006-07-03 |
2014-01-10 |
Чарльз Дэвид ЭДЕЙР |
Композиция для модулирования экспрессии молекул клеточной адгезии
|
US8067179B2
(en)
|
2006-11-30 |
2011-11-29 |
Research Development Foundation |
Immunoglobulin libraries
|
EP3103451A1
(de)
|
2007-01-12 |
2016-12-14 |
University of Maryland, Baltimore |
Targeting des ncca-atp-kanals für organschutz nach einer ischämischen episode
|
KR100855299B1
(ko)
*
|
2007-02-16 |
2008-08-29 |
건국대학교 산학협력단 |
인간 il-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 il-32측정법
|
US8629245B2
(en)
|
2007-05-01 |
2014-01-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
US20090010966A1
(en)
*
|
2007-06-21 |
2009-01-08 |
Angelica Therapeutics, Inc. |
Modified diphtheria toxins
|
EP3293269A1
(de)
|
2007-08-03 |
2018-03-14 |
MUSC Foundation For Research Development |
Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
|
US9605035B2
(en)
|
2008-01-10 |
2017-03-28 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
EP2268297A4
(de)
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
Modifizierte toxine
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
CA2743057C
(en)
|
2008-11-07 |
2019-11-26 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
|
US20110287088A1
(en)
|
2008-12-03 |
2011-11-24 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
WO2011044553A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
EP2673299B1
(de)
|
2011-02-07 |
2017-05-10 |
Research Development Foundation |
Manipulierte immunglobulin-fc-polypeptide
|
EA028805B1
(ru)
|
2011-04-01 |
2018-01-31 |
Иммьюноджен, Инк. |
Способы повышения эффективности folr1 терапии рака
|
HUE039009T2
(hu)
|
2011-08-05 |
2018-12-28 |
Res Found Dev |
Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
|
CA2845259A1
(en)
|
2011-08-15 |
2013-02-21 |
The University Of Chicago |
Compositions and methods related to antibodies to staphylococcal protein a
|
WO2013142299A1
(en)
|
2012-03-20 |
2013-09-26 |
Biogen Idec Ma Inc. |
Jcv neutralizing antibodies
|
CA2910320A1
(en)
|
2012-04-26 |
2013-10-31 |
University Of Chicago |
Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
|
EP3492101A3
(de)
|
2012-05-10 |
2019-10-23 |
Massachusetts Institute Of Technology |
Mittel zur influenzaneutralisierung
|
EP2882453B1
(de)
|
2012-08-07 |
2021-01-06 |
Massachusetts Institute of Technology |
Antikörper gegen das denguevirus und verwendungen davon
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
US9803014B2
(en)
|
2012-10-24 |
2017-10-31 |
Research Development Foundation |
JAM-C antibodies and methods for treatment of cancer
|
US9388397B2
(en)
|
2013-02-15 |
2016-07-12 |
Research Development Foundation |
Deimmunized gelonin molecules and therapies
|
CN110041427B
(zh)
|
2013-03-15 |
2023-05-23 |
本质生命科学有限公司 |
抗铁调素抗体及其用途
|
US10059750B2
(en)
|
2013-03-15 |
2018-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
ES2935257T3
(es)
|
2013-03-15 |
2023-03-03 |
Univ Chicago |
Métodos y composiciones relacionadas con la actividad de las células T
|
ES2945160T3
(es)
|
2013-03-15 |
2023-06-28 |
Gladiator Biosciences Inc |
Dominios Gla como agentes terapéuticos
|
US10526375B2
(en)
|
2013-06-05 |
2020-01-07 |
Massachusetts Institute Of Technology |
Human Adaptation of H7 HA
|
CA2916694C
(en)
|
2013-06-28 |
2023-01-17 |
Baylor Research Institute |
Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
|
CN106659909B
(zh)
|
2013-08-21 |
2022-01-11 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
HUE055856T2
(hu)
|
2013-08-30 |
2021-12-28 |
Immunogen Inc |
Antitestek és vizsgálatok a folsavreceptor 1 kimutatására
|
CA2965327C
(en)
|
2013-11-08 |
2023-05-09 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
EP3992210A1
(de)
|
2014-01-13 |
2022-05-04 |
Baylor Research Institute |
Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
|
EP3099719B1
(de)
|
2014-01-29 |
2020-04-01 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen die muc1-c/extrazelluläre domäne (/muc1-c/ecd)
|
SG11201606163QA
(en)
|
2014-02-11 |
2016-08-30 |
Massachusetts Inst Technology |
Novel full spectrum anti-dengue antibody
|
CN106415269B
(zh)
|
2014-05-08 |
2020-11-27 |
贵州美鑫达医疗科技有限公司 |
直接免疫组织化学测定
|
WO2015179435A1
(en)
|
2014-05-19 |
2015-11-26 |
Bayer Healthcare Llc |
Optimized humanized monoclonal antibodies against activated protein c and uses thereof
|
WO2016033225A2
(en)
|
2014-08-27 |
2016-03-03 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
AU2015321462B2
(en)
|
2014-09-22 |
2020-04-30 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
US10457737B2
(en)
|
2015-02-09 |
2019-10-29 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
AU2016222599B2
(en)
|
2015-02-25 |
2020-03-19 |
The Board Of Regents Of The University Of Texas System |
Antibody-mediated neutralization of Marburg virus
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
JP6987068B2
(ja)
|
2015-11-09 |
2021-12-22 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
癌マーカーおよび治療標的としてのグリピカン2
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
CN108601811A
(zh)
|
2015-12-04 |
2018-09-28 |
得克萨斯州大学系统董事会 |
用于免疫治疗的slc45a2肽
|
JP7098527B2
(ja)
|
2016-02-26 |
2022-07-11 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
コネキシン(Cx)43ヘミチャネル結合抗体及びその使用
|
KR102367074B1
(ko)
|
2016-03-29 |
2022-02-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
WO2018005926A1
(en)
|
2016-07-01 |
2018-01-04 |
The General Hospital Corporation |
Granzyme b directed imaging and therapy
|
KR20190031299A
(ko)
|
2016-07-20 |
2019-03-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
|
WO2018126183A2
(en)
|
2016-12-29 |
2018-07-05 |
The General Hospital Corporation |
Her3 peptides for imaging and radiotherapy
|
US10908168B2
(en)
|
2017-01-31 |
2021-02-02 |
Vanderbilt University |
Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
BR112020003533A2
(pt)
|
2017-08-25 |
2020-11-17 |
Five Prime Therapeutics, Inc. |
anticorpos b7-h4 e métodos de uso dos mesmos
|
EP3679128A1
(de)
|
2017-09-05 |
2020-07-15 |
GLAdiator Biosciences, Inc. |
Verfahren zum targeting von exosomen
|
DE112018005145T5
(de)
|
2017-09-15 |
2020-07-23 |
The Regents Of The University Of California |
Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
|
EP3694545A4
(de)
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
|
EP3735589A2
(de)
|
2018-01-05 |
2020-11-11 |
Vanderbilt University |
Antikörpervermittelte neutralisierung des chikungunya-virus
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
US20210214445A1
(en)
|
2018-03-23 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
CA3109366A1
(en)
|
2018-09-13 |
2020-03-19 |
The Board Of Regents Of The University Of Texas System |
Novel lilrb4 antibodies and uses thereof
|
JP2022524175A
(ja)
|
2018-11-02 |
2022-04-28 |
オクラホマ メディカル リサーチ ファウンデーション |
Eltd1に対するモノクローナル抗体及びその使用
|
EP3886982A1
(de)
|
2018-11-28 |
2021-10-06 |
Oregon Health & Science University |
Therapeutischer faktor-xii-antikörper
|
US20230132386A9
(en)
|
2019-02-13 |
2023-04-27 |
Cytosite Biopharma Inc. |
Granzyme b directed imaging and therapy
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
CA3145278A1
(en)
|
2019-07-26 |
2021-02-04 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
EP4041767A1
(de)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
AU2021220847A1
(en)
|
2020-02-11 |
2022-09-01 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
GB202105804D0
(en)
|
2020-11-20 |
2021-06-09 |
Univ Cape Town |
Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
JP2024512392A
(ja)
|
2021-03-08 |
2024-03-19 |
イミュノジェン・インコーポレーテッド |
がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|